114 related articles for article (PubMed ID: 27177463)
1. Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms.
Diamanti S; Nikitakis N; Rassidakis G; Doulis I; Sklavounou A
Oral Dis; 2016 Oct; 22(7):620-9. PubMed ID: 27177463
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.
Nikitakis NG; Scheper MA; Papanikolaou VS; Sklavounou A; Sauk JJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun; 107(6):837-43. PubMed ID: 19272817
[TBL] [Abstract][Full Text] [Related]
3. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of oestrogen receptor-α and progesterone receptor in salivary gland tumours.
Kolude B; Adisa A; Adeyemi B; Lawal A
J Oral Pathol Med; 2013 Oct; 42(9):716-9. PubMed ID: 23601083
[TBL] [Abstract][Full Text] [Related]
5. Expression of upstream and downstream targets of mTOR pathway in seven cases of secretory carcinoma of salivary gland origin.
Custódio M; Sedassari BT; Altemani A; Rodrigues MFSD; Nunes FD; de Sousa SCOM
Eur Arch Otorhinolaryngol; 2021 Jan; 278(1):279-283. PubMed ID: 32577896
[TBL] [Abstract][Full Text] [Related]
6. Immunoprofile of c-MET/PI3K signaling in human salivary gland tumors.
Vasconcelos AC; Wagner VP; Meurer L; Vargas PA; de Souza LB; Fonseca FP; Squarize CH; Castilho RM; Martins MD
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Aug; 120(2):238-47. PubMed ID: 26117810
[TBL] [Abstract][Full Text] [Related]
7. Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?
Clauditz TS; Gontarewicz A; Bokemeyer C; Sauter G; Knecht R; Münscher A; Wilczak W
J Oral Pathol Med; 2013 Nov; 42(10):769-73. PubMed ID: 23521157
[TBL] [Abstract][Full Text] [Related]
8. Immunoreactivity patterns of tight junction proteins are useful for differential diagnosis of human salivary gland tumors.
Aoyama T; Takasawa A; Murata M; Osanai M; Takano K; Hasagawa T; Sawada N
Med Mol Morphol; 2019 Mar; 52(1):23-35. PubMed ID: 29955965
[TBL] [Abstract][Full Text] [Related]
9. Chemokine and chemokine receptor patterns in patients with benign and malignant salivary gland tumors: a distinct role for CCR7.
Haghshenas MR; Ashraf MJ; Khademi B; Ghaderi A; Erfani N; Razmkhah M
Eur Cytokine Netw; 2017 Mar; 28(1):27-35. PubMed ID: 28840842
[TBL] [Abstract][Full Text] [Related]
10. RANK and RANKL Expression in Salivary Gland Tumors.
Aslan F; Küçük Ü
Ear Nose Throat J; 2020 Aug; 99(7):475-480. PubMed ID: 32525717
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
12. Salivary gland tumors at in vivo proton MR spectroscopy.
King AD; Yeung DK; Ahuja AT; Tse GM; Yuen HY; Wong KT; van Hasselt AC
Radiology; 2005 Nov; 237(2):563-9. PubMed ID: 16244265
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
[TBL] [Abstract][Full Text] [Related]
14. Could a possible crosstalk between AMPK and TGF-β signaling pathways be a key player in benign and malignant salivary gland tumors?
Ghahhari NM; Ghahhari HM; Kadivar M
Onkologie; 2012; 35(12):770-4. PubMed ID: 23207623
[TBL] [Abstract][Full Text] [Related]
15. Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression.
Cao Y; Liu H; Gao L; Lu L; Du L; Bai H; Li J; Said S; Wang XJ; Song J; Serkova N; Wei M; Xiao J; Lu SL
Neoplasia; 2018 Aug; 20(8):764-774. PubMed ID: 29958137
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
18. Reduced chromatin acetylation of malignant salivary gland tumors correlates with enhanced proliferation.
Wagner VP; Martins MD; Guimaraes DM; Vasconcelos AC; Meurer L; Vargas PA; Fonseca FP; Squarize CH; Castilho RM
J Oral Pathol Med; 2017 Oct; 46(9):792-797. PubMed ID: 28161900
[TBL] [Abstract][Full Text] [Related]
19. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
Sciascia Q; Pacheco D; McCoard SA
J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
